You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 293 No. 15, April 20, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Women's Health
 •Women's Health, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Urinary Placental Growth Factor and Preeclampsia

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The study by Dr Levine and colleagues1 showed that urinary placental growth factor (PlGF) was significantly lower beginning at 25 to 28 weeks of gestation among women who subsequently developed preeclampsia compared with normotensive controls. From an ancillary study, they also concluded that a low urinary PlGF concentration at 21 to 32 weeks of gestation may distinguish preeclampsia from intrauterine growth retardation in normotensive women. However, 239 women with term preeclampsia (37 weeks) were excluded from both the main and ancillary studies. It is therefore possible that many women who delivered a small-for-gestational-age (SGA) infant because of uteroplacental insufficiency were excluded because they developed the later preeclampsia that is often observed in these circumstances.2

Moreover, differentiating between women with preeclampsia before 37 weeks (of whom 85% delivered <37 weeks) and women who remained normotensive but delivered an SGA infant (of whom only 10% delivered <37 weeks) has . . . [Full Text of this Article]

Lionel Carbillon, MD, PhD
lionel.carbillon@jvr.ap-hop-paris.fr

Michele Uzan, MD
Department of Obstetrics and Gynecology
Assistance Publique-Hôpitaux de Paris
Paris, France



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Urinary Placental Growth Factor and Preeclampsia—Reply
Richard J. Levine, Franklin H. Epstein, and S. Ananth Karumanchi
JAMA. 2005;293(15):1857-1858.
EXTRACT | FULL TEXT  

Urinary Placental Growth Factor and Risk of Preeclampsia
Richard J. Levine, Ravi Thadhani, Cong Qian, Chun Lam, Kee-Hak Lim, Kai F. Yu, Anastasia L. Blink, Benjamin P. Sachs, Franklin H. Epstein, Baha M. Sibai, Vikas P. Sukhatme, and S. Ananth Karumanchi
JAMA. 2005;293(1):77-85.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Circulating Levels of the Antiangiogenic Marker Soluble FMS-Like Tyrosine Kinase 1 Are Elevated in Women With Pregestational Diabetes and Preeclampsia: Angiogenic markers in preeclampsia and preexisting diabetes
Cohen et al.
Diabetes Care 2007;30:375-377.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.